About ESSA Pharma (TSE:EPI)
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor. The company was founded in 2009 and is headquartered in Vancouver, Canada.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on Assets130.13%
Frequently Asked Questions for ESSA Pharma (TSE:EPI)
What is ESSA Pharma's stock symbol?
ESSA Pharma trades on the Toronto Stock Exchange (TSX) under the ticker symbol "EPI."
When will ESSA Pharma make its next earnings announcement?
Who are some of ESSA Pharma's key competitors?
Some companies that are related to ESSA Pharma include Petrowest Corp (PRW), Enterprise Group (E), GASFRAC Energy Services (GFS), Primero Mining Corp. (P), New Millennium Iron Corp (NML), San Gold Corp. (SGR), Bri-Chem Corp (BRY), Karnalyte Resources (KRN), Zargon Oil & Gas Ltd (ZAR), Eagle Energy (EGL), DragonWave (DRWI), Roots Corp (ROOT), Spyglass Resources Corp (SGL), Itafos (MBC), Niko Resources (NKO), Southern Pacific Resource Corp. (STP), Labrador Iron Mines Holdings Limited (LIM) and Mainstreet Health Investments (HLP.U).
Who are ESSA Pharma's key executives?
ESSA Pharma's management team includes the folowing people:
- Richard M. Glickman LL.D., Chairman of the Board (Age 57)
- David Ross Parkinson M.D., President, Chief Executive Officer, Director (Age 67)
- David Wood, Chief Financial Officer (Age 57)
- Peter Virsik, Chief Operating Officer, Executive Vice President
- Raymond L. Andersen, Chief Technology Officer, Director (Age 67)
- Marianne D. Sadar, Chief Scientific Officer, Director (Age 53)
- Frank Perabo, Chief Medical Officer (Age 50)
- Franklin M. Berger, Director (Age 67)
- Scott Requadt J.D., Director
- Gary Sollis, Director (Age 61)
How do I buy ESSA Pharma stock?
Shares of ESSA Pharma and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is ESSA Pharma's stock price today?
One share of ESSA Pharma stock can currently be purchased for approximately C$0.34.
How big of a company is ESSA Pharma?
ESSA Pharma has a market capitalization of C$10.47 million.
How can I contact ESSA Pharma?
ESSA Pharma's mailing address is 999 Broadway W Suite 720, VANCOUVER, BC V5Z 1K5, Canada. The company can be reached via phone at +1-778-3310962.
MarketBeat Community Rating for ESSA Pharma (EPI)MarketBeat's community ratings are surveys of what our community members think about ESSA Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for ESSA Pharma (TSE:EPI) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 1 Hold Rating, 1 Buy Rating, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 2.50)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for ESSA Pharma (TSE:EPI)
Analysts' Ratings History for ESSA Pharma (TSE:EPI)
(Data available from 11/23/2015 forward)
|9/12/2017||Bloom Burton||Downgrade||Buy -> Hold|
|8/2/2017||Dawson James||Reiterated Rating||Buy|
Earnings History for ESSA Pharma (TSE:EPI)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for ESSA Pharma (TSE:EPI)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for ESSA Pharma (TSE:EPI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for ESSA Pharma (TSE EPI)
Insider Trades by Quarter for ESSA Pharma (TSE EPI)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
Latest Headlines for ESSA Pharma (TSE EPI)
Financials are not available for this stock.
ESSA Pharma (TSE EPI) Chart for Thursday, November, 23, 2017